Cryoablation of early lung cancers – pro
There is limited evidence for the possible use of cryoablation for early-stage NSCLC. A 2014 review found 5 case series, including patients with NSCLC and additional observational studies. These studies were very heterogeneous in terms of patient selection, cryoablation procedure, and tumor characteristics. Since only two studies reported estimated 3-year survivals, the therapeutic value of cryoablation has not yet been established. However,it is now known percutaneous cryoablation for lung tumor could be performed minimally invasively with acceptable complication rates. The early results of cryoablation for the treatment of patients with NSCLC appear feasible and encouraging, suggesting its potential to be one of the treatment options for patients who are unfit for surgery. Randomized trials comparing cryoablation with surgery are required.
Masanori Inoue, Seishi Nakatsuka, and Masahiro JinzakiReview Article: Cryoablation of Early-Stage Primary Lung Cancer. BioMed Research International Volume 2014 (2014), Article ID 521691, 8 pages
e Baere T, Farouil G, Woodrum DA, et al. Evaluatiing cryoablation of metastatic lung/pleura tumors in patients – safety and efficacy (ECLIPSE), preliminary safety outcomes. Presented at: Society of Interventional Radiology’s 38th Annual Scientific Meeting; April 13–18, 2013; New Orleans, LA. Abstract 33. – See more at: http://www.onclive.com/publications/Oncology-live/2013/July-2013/Cryoablation-May-Offer-Option-for-Metastatic-Lung-Tumors#sthash.xsG3TmNH.dpuf
AUYashiro H, Nakatsuka S, Inoue M, Kawamura M, Tsukada N, Asakura K, Yamauchi Y, Hashimoto K, Kuribayashi S, Factors affecting local progression after percutaneous cryoablation of lung tumors. SOJ Vasc Interv Radiol. 2013 Jun;24(6):813-21.